IL163586A0 - Methods of preventing or treating brain ischemia or brain injury - Google Patents

Methods of preventing or treating brain ischemia or brain injury

Info

Publication number
IL163586A0
IL163586A0 IL16358603A IL16358603A IL163586A0 IL 163586 A0 IL163586 A0 IL 163586A0 IL 16358603 A IL16358603 A IL 16358603A IL 16358603 A IL16358603 A IL 16358603A IL 163586 A0 IL163586 A0 IL 163586A0
Authority
IL
Israel
Prior art keywords
brain
preventing
methods
treating
ischemia
Prior art date
Application number
IL16358603A
Other languages
English (en)
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of IL163586A0 publication Critical patent/IL163586A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
IL16358603A 2002-02-21 2003-02-20 Methods of preventing or treating brain ischemia or brain injury IL163586A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35906102P 2002-02-21 2002-02-21
PCT/US2003/005090 WO2003072543A2 (en) 2002-02-21 2003-02-20 Methods of preventing or treating brain ischemia or brain injury

Publications (1)

Publication Number Publication Date
IL163586A0 true IL163586A0 (en) 2005-12-18

Family

ID=27766036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16358603A IL163586A0 (en) 2002-02-21 2003-02-20 Methods of preventing or treating brain ischemia or brain injury

Country Status (7)

Country Link
US (2) US7202211B2 (sl)
EP (1) EP1476179A2 (sl)
JP (1) JP2005518443A (sl)
AU (1) AU2003223184A1 (sl)
CA (1) CA2476765A1 (sl)
IL (1) IL163586A0 (sl)
WO (1) WO2003072543A2 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072543A2 (en) * 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341762A (en) * 1981-04-07 1982-07-27 Haast William E Use of snake venoms for treatment of neurological and related disorders
US6316602B1 (en) * 1994-05-03 2001-11-13 Binie V. Lipps Beta taipoxin as a cell growth factor and method
US5767252A (en) 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp
US6124610A (en) * 1998-06-26 2000-09-26 Advanced Micro Devices, Inc. Isotropically etching sidewall spacers to be used for both an NMOS source/drain implant and a PMOS LDD implant
AU5731800A (en) 1999-06-09 2000-12-28 Johns Hopkins University School Of Medicine, The Method for identifying compounds which affect synaptogenesis
EP1101820A1 (en) 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
AU2001237543A1 (en) 2000-02-24 2001-09-03 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2003072543A2 (en) * 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury

Also Published As

Publication number Publication date
CA2476765A1 (en) 2003-09-04
WO2003072543A2 (en) 2003-09-04
WO2003072543A3 (en) 2004-05-21
US7202211B2 (en) 2007-04-10
US20070173453A1 (en) 2007-07-26
AU2003223184A1 (en) 2003-09-09
JP2005518443A (ja) 2005-06-23
EP1476179A2 (en) 2004-11-17
AU2003223184A8 (en) 2003-09-09
US20030219430A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
AU2003286567A8 (en) Methods for the treatment of skin disorders
EP1617805A4 (en) METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
EP1545700A4 (en) METHOD OF TREATING CENTRAL NERVOUS SYSTEM DAMAGE
AU2003295537A8 (en) Methods of treating cerebral ischemia
EP1635813A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
EP1636359A4 (en) METHODS OF TREATING PAIN
EP1535971A4 (en) TREATED PIGMENT, ITS USE, AND COMPOUND FOR THE TREATMENT OF PIGMENTS
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
EP1505961A4 (en) METHOD FOR TREATING ALLERGIC REACTIONS
EP1677794A4 (en) METHODS OF TREATING DISORDERS
HUS1300035I1 (hu) Dihidroimidazolonok alkalmazása epilepszia kezelésére kutyákban
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
AU2003249181A8 (en) Methods for treating or preventing ischemic injury
GB0213869D0 (en) The treatment of pain
AU2003223184A8 (en) Methods of preventing or treating brain ischemia or brain injury
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
EP1560592A4 (en) TREATMENT OF ALLGIELES
GB0217493D0 (en) Novel methods of treatment
PL1867644T3 (pl) Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
GB0221712D0 (en) Methods of treatment
IL161630A0 (en) Methods of treating endometreosis
AUPS165902A0 (en) Methods of treating brca associated disorder
ZA200604723B (en) Agents for preventing and/or treating higher brain dysfunctions
GB0327975D0 (en) Methods of treatment